Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (formerly listed on Nasdaq under the symbol VRNA) generated a steady stream of news as a biopharmaceutical company focused on chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Its news flow has covered the clinical development, regulatory progress and commercialization of its first-in-class COPD maintenance therapy Ohtuvayre (ensifentrine), as well as major corporate events culminating in its acquisition by Merck.
News articles about Verona Pharma include updates on the Phase 3 ENHANCE program for Ohtuvayre, where the drug met primary endpoints in ENHANCE-1 and ENHANCE-2 with statistically significant and clinically meaningful improvements in lung function. The company has also announced multiple scientific presentations at leading respiratory conferences such as the European Respiratory Society (ERS) International Congress and the American Thoracic Society (ATS) Conference, highlighting subgroup analyses on exacerbation rates, dyspnea, quality of life and outcomes in patients with comorbid conditions like cardiac disorders and type 2 diabetes.
Investors following VRNA-related news will also find corporate and financial updates, including quarterly financial results that detail Ohtuvayre net sales, prescription trends, prescriber adoption, and Verona’s funding and debt arrangements. Additional releases have described regulatory milestones, such as approval of Ohtuvayre in Macau through a development partner in Greater China and ongoing regulatory activities for potential marketing applications in other regions.
A key component of Verona Pharma’s news history is its strategic transaction with Merck. Press releases and SEC-related communications outline the July 2025 definitive agreement for Merck to acquire Verona Pharma, subsequent shareholder approval, court sanction of the scheme of arrangement, and Merck’s October 2025 announcement that the acquisition had closed and Verona Pharma had become a wholly owned subsidiary. Coverage of this process includes details of the cash consideration per ordinary share and per ADS and the resulting delisting of VRNA from the Nasdaq Global Market.
This news page serves as an archive of Verona Pharma’s historical announcements, from clinical and commercial milestones for Ohtuvayre to the corporate steps leading to its integration into Merck. Readers interested in the evolution of VRNA, the development of ensifentrine-based therapies, and the transaction that removed Verona Pharma from public markets can use this feed to review the company’s key public communications over time.
Verona Pharma (VRNA) has amended its strategic financing agreements with Oaktree Capital Management and OMERS Life Sciences, marking significant changes to its capital structure. The company has:
- Repurchased the Revenue Interest Purchase and Sale Agreement (RIPSA) $100 million obligation
- Increased its term loan facility to $450 million with improved terms
- Borrowed $125 million from an expanded Tranche C, bringing total outstanding debt to $250 million
- Reduced interest rates from 11% to 9.7%, with potential further reduction to 9.35% upon meeting sales milestones
- Gained ability to secure up to $75 million in working capital revolving credit
The refinancing reflects the successful launch and growing prescriptions of Ohtuvayre™ (ensifentrine), their COPD maintenance treatment, providing increased financial flexibility and simplified balance sheet structure.
Verona Pharma (VRNA) reported strong Q4 and full year 2024 results for Ohtuvayre, their first FDA-approved COPD maintenance treatment. Q4 net product sales reached $36.6 million, contributing to full year sales of $42.3 million.
The company highlighted growing prescription momentum, with over 4,600 unique prescribers and approximately 55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025. The drug received its first approval outside the US in Macau.
Financial results show Q4 net loss of $33.8 million and full year net loss of $173.4 million. Cash position remained strong at $399.8 million as of December 31, 2024. The company is advancing Phase 2 programs in bronchiectasis and a fixed-dose combination therapy for COPD, with plans to initiate a Phase 2b trial in H2 2025.
Verona Pharma (Nasdaq: VRNA) has announced its participation in two major healthcare investor conferences in March 2025. The company will present corporate overviews at the TD Cowen 45th Annual Health Care Conference in Boston on March 3 at 11:10 a.m. ET, and at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10 at 8:40 a.m. ET.
The company specializes in developing treatments for chronic respiratory diseases, with their flagship product Ohtuvayre™ (ensifentrine), the first inhaled COPD maintenance therapy combining bronchodilator and anti-inflammatory properties. Webcasts of both presentations will be available on the company's website.
Verona Pharma (Nasdaq: VRNA) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025. The company will host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the results and provide a corporate update.
The company specializes in developing and commercializing innovative therapies for chronic respiratory diseases. Their first commercial product, Ohtuvaire (ensifentrine), is an inhaled maintenance treatment for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The treatment shows potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.
Verona Pharma reports strong performance for their newly launched COPD treatment Ohtuvayre (ensifentrine), with approximately $36 million in net product sales for Q4 2024 and $42 million for full year 2024. The drug, launched after FDA approval in June 2024, has gained significant traction with over 3,500 unique healthcare professionals prescribing it and more than 16,000 prescriptions filled in 2024.
Key achievements include approximately 45% of Tier 1 HCPs prescribing Ohtuvayre, monthly prescription growth exceeding 35% in Q4, and about one-third of prescriptions being refills. The company maintains approximately two weeks of inventory at specialty pharmacies and reports strong cash position of approximately $400 million as of December 31, 2024.
Verona Pharma (Nasdaq: VRNA) announces its participation in two major healthcare investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 12:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Miami on December 4 at 3:00 p.m. ET. Webcasts of both presentations will be available on the company's website. Verona Pharma specializes in developing therapies for chronic respiratory diseases, with their first commercial product Ohtuvayre™ (ensifentrine) being a dual-action COPD treatment.
Verona Pharma (Nasdaq: VRNA) announces its participation in the upcoming Jefferies London Healthcare Conference. The company's senior management will deliver a company overview on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
A webcast of the presentation will be accessible through the Events and Presentations section on the Investors page of Verona Pharma's website. The company has provided contact information for investor relations, US investor enquiries, and international/US media enquiries for those seeking additional information.
Verona Pharma reported strong Q3 2024 results, with Ohtuvayre™ (ensifentrine) launch generating $5.6 million in net sales during its first seven weeks. October sales exceeded Q3 performance, with over 5,000 prescriptions filled and 2,200 unique prescribers across COPD patients. The company initiated two Phase 2 trials: a dose-ranging trial with glycopyrrolate and a trial for non-cystic fibrosis bronchiectasis. Cash position stood at $336.0 million, expected to fund operations through 2026. Q3 expenses increased with R&D at $10.6 million and SG&A at $35.2 million, resulting in a net loss of $43.0 million.
Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, www.veronapharma.com, with an audio replay available for 90 days.
Verona Pharma announces six analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for COPD treatment to be presented at CHEST 2024. The presentations include four oral and two poster sessions, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups. Key findings show improvements in lung function, symptoms, and quality of life, as well as reduced exacerbation rates, regardless of COPD severity, smoking status, or chronic bronchitis presence.
Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. It's the first novel inhaled mechanism for COPD maintenance treatment in over 20 years. The analyses will also present data on Ohtuvayre's impact on reducing COPD-related healthcare resource utilization over 48 weeks.